APA

Clopes A., Gasol M., Cajal R., Segú L., Crespo R., Mora R., Simon S., Cordero L. A., Calle C., Gilabert A. & Germà J. R. (20170629). Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. : Journal of medical economics.

Chicago

Clopes Ana, Gasol Montse, Cajal Rosana, Segú Luis, Crespo Ricard, Mora Ramón, Simon Susana, Cordero Luis A, Calle Candela, Gilabert Antoni and Germà Josep R. 20170629. Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. : Journal of medical economics.

Harvard

Clopes A., Gasol M., Cajal R., Segú L., Crespo R., Mora R., Simon S., Cordero L. A., Calle C., Gilabert A. and Germà J. R. (20170629). Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. : Journal of medical economics.

MLA

Clopes Ana, Gasol Montse, Cajal Rosana, Segú Luis, Crespo Ricard, Mora Ramón, Simon Susana, Cordero Luis A, Calle Candela, Gilabert Antoni and Germà Josep R. Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. : Journal of medical economics. 20170629.